Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B84a70ab8bcfd1cf4cf0c769c0e93b5c6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B84a70ab8bcfd1cf4cf0c769c0e93b5c6 NCIT_P378 "NCI" @default.
- B84a70ab8bcfd1cf4cf0c769c0e93b5c6 type Axiom @default.
- B84a70ab8bcfd1cf4cf0c769c0e93b5c6 annotatedProperty IAO_0000115 @default.
- B84a70ab8bcfd1cf4cf0c769c0e93b5c6 annotatedSource NCIT_C97938 @default.
- B84a70ab8bcfd1cf4cf0c769c0e93b5c6 annotatedTarget "The s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression." @default.